AbbVie Celebrates Official Launch - - BioPharm International

ADVERTISEMENT

AbbVie Celebrates Official Launch



AbbVie, a research-focused, specialty biopharmaceutical company that was spun off from Abbott, was officially launched on Jan. 2, 2013.  The new company will employ approximately 21,000 people in more than 40 countries, according to AbbVie’s news release.

The new company’s portfolio includes both growth brands and durable performers, including HUMIRA (adalimumab), AndroGel (testosterone gel), Lupron (leuprolide), Synagis (palivizumab, manufactured by MedImmune), Creon (pancrelipase), Synthroid (levothyroxine sodium), Kaletra (lopinavir/ritonavir), Norvir (ritonavir), and Zemplar (paricalcitol). In addition, AbbVie’s pipeline contains compounds in more than 20 mid- to late-stage clinical programs as well as discovery efforts in diseases including Hepatitis C, rheumatoid arthritis, psoriasis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, spondyloarthropathies, multiple myeloma, and endometriosis.

"Our commitment at AbbVie is to build on Abbott's 125-year heritage and address some of the world's most serious health issues," said Richard A. Gonzalez, AbbVie’s chairman of the board and chief executive officer, in the press release. "We intend AbbVie's enduring legacy to be one of finding treatments for patients with serious health care needs."

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines

Click here